Drugs Made In America Acquisition (DMAAR) EBT (2025)

Drugs Made In America Acquisition (DMAAR) posted EBT of $212958.0 for Q4 2025, down 90.25% on a QoQ basis from $2.2 million in Q3 2025.

Drugs Made In America Acquisition (DMAAR) EBT (2025) Analysis & Trends

Drugs Made In America Acquisition's EBT history runs 1 years deep, the most recent figure standing at $212958.0 for Q4 2025.

Quarterly EBT changed N/A year-over-year to $212958.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (changed N/A YoY) and the FY2025 annual result came in at $5.9 million, up 2222.83% from the prior year.
EBT was $212958.0 for Q4 2025 at Drugs Made In America Acquisition, down from $2.2 million in the prior quarter.
Across five years, EBT topped out at $2.3 million in Q2 2025 and bottomed at $212958.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	SIM Acquisition Corp. I	314.52 Mn	314.52 Mn	-	2.03 Mn
2	Thayer Ventures Acquisition	208.29 Mn	208.29 Mn	-	-394,142.00
3	Newbury Street II Acquisition	185.26 Mn	185.26 Mn	-	1.38 Mn
4	Dynamix	178.78 Mn	178.78 Mn	-	-728,564.00
5	Hallmark Venture	103.01 Mn	102.76 Mn	-	-273,496.00
6	Voyager Acquisition	99.58 Mn	99.45 Mn	-	-
7	Gores Holdings X	95.80 Mn	95.37 Mn	-	1.88 Mn
8	Archimedes Tech SPAC Partners	89.88 Mn	89.88 Mn	-	2.05 Mn
9	Cohen Circle Acquisition	80.05 Mn	80.05 Mn	-	1.87 Mn
10	Drugs Made In America Acquisition	1.46 Mn	1.46 Mn	-	212,958.00

Download Data